A
Ailin Li
Researcher at China Medical University (PRC)
Publications - 25
Citations - 288
Ailin Li is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Lung cancer & Cyclin D1. The author has an hindex of 9, co-authored 25 publications receiving 207 citations.
Papers
More filters
Journal ArticleDOI
Overexpression of NEDD9 is Associated with Altered Expression of E-Cadherin, β -Catenin and N-Cadherin and Predictive of Poor Prognosis in non-Small Cell Lung Cancer
Yuan Miao,Ailin Li,Liang Wang,Chuifeng Fan,Xiupeng Zhang,Hong-Tao Xu,Lian-He Yang,Yang Liu,Enhua Wang +8 more
TL;DR: In conclusion, overexpression of NEDD9 correlates with altered expression of EMT markers, increased lymph node metastasis and poorer survival in lung cancer.
Journal ArticleDOI
Clinicopathological significance of claudin-4 in gastric carcinoma
Jin-Liang Zhu,Peng Gao,Zhenning Wang,Yongxi Song,Ailin Li,Ying-Ying Xu,Mei-Xian Wang,Huimian Xu +7 more
TL;DR: The findings in this study demonstrate claudin-4 aberrant expression in gastric cancer and precursor lesions and could serve as a basis for identifying Gastric cancer of the intermediate type.
Journal ArticleDOI
Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway.
Xiupeng Zhang,Yang Liu,Chuifeng Fan,Liang Wang,Ailin Li,Haijing Zhou,Lin Cai,Yuan Miao,Qingchang Li,Xueshan Qiu,Enhua Wang +10 more
TL;DR: Lasp1 facilitated tumor proliferation and invasion of NSCLC through directly binding to FAK and enhancing the phosphorylation of FAK (Tyr397) and AKT (Ser473) and Lasp1 may be a novel therapeutic target in the treatment of NSLI patients.
Journal ArticleDOI
ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients.
TL;DR: It is identified that ARHGEF39 promotes tumor growth and invasion by activating the Rac1-P38-ATF2 signaling pathway, as well as increasing the expression of Cyclin A2, Cyclin D1, and MMP2 in NSCLC cells.
Journal ArticleDOI
Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer.
Lin Cai,Jingduo Li,Jing Zhao,Yingxue Guo,Menghua Xie,Xiupeng Zhang,Liang Wang,Hua Tian,Ailin Li,Qingchang Li,Yuan Miao +10 more
TL;DR: In vitro experiments revealed that Fbxo6 expression is correlated with early TNM stage and favorable overall survival of NSCLC patients and may be a useful prognosis marker and therapeutic target to overcome the chemoresistance of cisplatin‐based chemotherapy agents in NSCLc patients.